Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Investment analysts at Piper Jaffray Companies reduced their FY2018 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a report released on Thursday, November 1st. Piper Jaffray Companies analyst T. Van. Buren now forecasts that the biopharmaceutical company will earn ($6.10) per share for the year, down from their previous forecast of ($5.90). Piper Jaffray Companies has a “Buy” rating and a $125.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Agios Pharmaceuticals’ Q4 2018 earnings at ($1.65) EPS, Q4 2019 earnings at ($1.40) EPS and FY2019 earnings at ($6.05) EPS.
Several other analysts have also commented on AGIO. ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday. Oppenheimer reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Thursday. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday. Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, September 5th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $123.00 target price on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Six investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $96.27.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.01). The company had revenue of $15.20 million for the quarter, compared to analyst estimates of $22.72 million. Agios Pharmaceuticals had a negative return on equity of 49.78% and a negative net margin of 461.78%. The firm’s revenue was up 33.8% on a year-over-year basis. During the same period last year, the business earned ($1.59) earnings per share.
A number of institutional investors and hedge funds have recently modified their holdings of AGIO. First Trust Advisors LP grew its holdings in Agios Pharmaceuticals by 58.8% in the third quarter. First Trust Advisors LP now owns 1,162,010 shares of the biopharmaceutical company’s stock valued at $89,614,000 after purchasing an additional 430,216 shares during the period. Woodford Investment Management Ltd acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $32,849,000. Wells Fargo & Company MN boosted its stake in shares of Agios Pharmaceuticals by 459.8% in the second quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock worth $34,315,000 after acquiring an additional 334,617 shares during the last quarter. Castleark Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $8,114,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Agios Pharmaceuticals in the first quarter worth approximately $6,268,000. 93.61% of the stock is currently owned by institutional investors.
In other Agios Pharmaceuticals news, insider Christopher Bowden sold 1,700 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $80.03, for a total value of $136,051.00. Following the sale, the insider now directly owns 1,224 shares of the company’s stock, valued at $97,956.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, October 5th. The shares were sold at an average price of $69.79, for a total value of $209,370.00. Following the completion of the sale, the insider now directly owns 53,932 shares in the company, valued at $3,763,914.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,305 shares of company stock worth $1,734,343. 3.02% of the stock is owned by corporate insiders.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: What are the economic characteristics of a bear market?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.